Contact this trialFirst, we need to learn more about you.
Wee1 Kinase Inhibitor
Adavosertib for Cancer
Recruiting1 awardPhase 2
Orland Park, Illinois
This trial studies how well adavosertib works in patients with advanced or metastatic solid tumors that lack the SETD2 gene. Adavosertib may help stop tumor growth by blocking enzymes needed for cancer cells to grow. Adavosertib is a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, previously shown to have clinical activity in various cancers.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service